Medicare Part D coverage · methscopolamine bromide · RxCUI 314088
methscopolamine bromide 2.5 MG Oral Tablet
Per the CMS 2026 Part D formulary file, methscopolamine bromide 2.5 MG Oral Tablet is covered by 2,054 Medicare Part D plans (40.7% of enrollable products), averaging Tier 3, with prior authorization required on 9.5% of covering formularies.
- 40.7%
- Plan coverage
- 2,054
- Plans covering
- T3
- Avg tier
- 9.5%
- Prior auth required
What the CMS Formulary Data Shows for methscopolamine bromide 2.5 MG Oral Tablet
Per the CMS 2026 Part D formulary file, methscopolamine bromide 2.5 MG Oral Tablet (RxNorm concept RXCUI 314088, generic name methscopolamine bromide) appears on 74 distinct formulary files spanning 2,054 Medicare Part D plan offerings - 40.7% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.
Real-world access to methscopolamine bromide 2.5 MG Oral Tablet depends on utilization management as much as tier placement: 9.5% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,596 Part D beneficiaries filled methscopolamine bromide 2.5 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $836,854 and an average per-beneficiary annual cost of $524.34. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry methscopolamine bromide 2.5 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 74
- Plans covering
- 2,054
- Coverage rate
- 40.7%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 9.5% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,596
- Total spending
- $836,854
- Avg per beneficiary
- $524.34
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering methscopolamine bromide 2.5 MG Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CareAdvantage (HMO D-SNP) | SAN Mateo Health Commission | T1 | No | $0 | CA |
| Gold Coast Health Plan Total Care Advantage (HMO D-SNP) | Ventura County Medi-Cal Managed Care Commission | T1 | No | $0 | CA |
| Blue Cross Medicare Advantage Dual Care Plus (HMO D-SNP) | Health Care Service Corporation | T1 | No | $0 | NM |
| Blue Cross MA Dual Care Plus Preferred (PPO D-SNP) | Health Care Service Corporation | T1 | No | $0 | NM |
| SecureBlue (HMO D-SNP) | HMO Minnesota | T1 | No | $0 | MN |
| Hamaspik Medicare Choice (HMO D-SNP) | Hamaspik, Inc. | T1 | No | $0 | NY |
| PHP (HMO C-snp) | Aids Healthcare Foundation | T1 | No | $0 | CA |
| VNS Health Total (HMO D-SNP) | VNS Choice | T1 | No | $0 | NY |
| Platino Blindao (HMO D-SNP) | Triple S Advantage, Inc. | T1 | No | $0 | PR |
| Platino Enlace (HMO D-SNP) | Triple S Advantage, Inc. | T1 | No | $0 | PR |
| Platino Advance (HMO D-snp) | Triple S Advantage, Inc. | T1 | No | $0 | PR |
| Platino Plus (HMO D-snp) | Triple S Advantage, Inc. | T1 | No | $0 | PR |
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) | Gateway Health Plan, Inc. | T1 | Yes | $0 | PA |
| Highmark Wholecare Medicare Assured Diamond (HMO D-SNP) | Gateway Health Plan, Inc. | T1 | Yes | $0 | PA |
| Highmark Health Options Duals (HMO D-SNP) | Highmark Health Options West Virginia Inc. | T1 | Yes | $0 | WV |
| Highmark Health Options Duals (HMO D-SNP) | Highmark Bcbsd, Inc. | T1 | Yes | $0 | DE |
| Leon MediExtra (HMO) | Leon Health, Inc. | T1 | No | $0 | FL |
| Leon MediDual (HMO D-SNP) | Leon Health, Inc. | T1 | No | $0 | FL |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is methscopolamine bromide 2.5 MG Oral Tablet covered by Medicare Part D?
Yes, methscopolamine bromide 2.5 MG Oral Tablet is covered by 2,054 Medicare Part D plans (40.7% of all Part D formularies).
What tier is methscopolamine bromide 2.5 MG Oral Tablet on Medicare Part D plans?
methscopolamine bromide 2.5 MG Oral Tablet averages Tier 3 across Part D plans, ranging from Tier 1 to Tier 4.
Does methscopolamine bromide 2.5 MG Oral Tablet require prior authorization?
9.5% of Part D formularies require prior authorization for methscopolamine bromide 2.5 MG Oral Tablet. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on methscopolamine bromide 2.5 MG Oral Tablet?
In 2023, total Medicare Part D spending on methscopolamine bromide 2.5 MG Oral Tablet was $836,854, covering 1,596 beneficiaries. The average spend per beneficiary was $524.34.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 120 ACTUAT albuterol 0.1 MG/ACTUAT / ipratropium bromide 0.02 MG/ACTUAT Inhalation Spray [Combivent] T3
- 24 HR paliperidone 3 MG Extended Release Oral Tablet T3
- naloxone hydrochloride 80 MG/ML Nasal Spray [Kloxxado] T3
- griseofulvin 250 MG Oral Tablet T3
- hydroxyurea 200 MG Oral Capsule [Droxia] T3
- hydromorphone hydrochloride 1 MG/ML Oral Solution T3
Similar prior-authorization rate
- doxycycline hyclate 100 MG Injection 9.5% PA
- 1 ML denosumab-nxxp 60 MG/ML Prefilled Syringe [Bildyos] 9.6% PA
- ceftazidime 200 MG/ML Injectable Solution [Tazicef] 9.4% PA
- nafcillin 100 MG/ML Injectable Solution 9.3% PA
- magnesium chloride 0.00148 MEQ/ML / monobasic potassium phosphate 0.0082 MG/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.0272 MEQ/ML / sodium chloride 0.0906 MEQ/ML / sodium gluconate 5 MG/ML / sodium phosphate, dibasic 0.12 MG/ML Injectable Solution [Isolyte S] 9.3% PA
- ampicillin 1000 MG / sulbactam 500 MG Injection 9.3% PA